ArticleCancer medicine2026
Sarcopenia in Oncological Patients Diagnostics, Screening, and Impact on Quality of Life, Fatigue, Handgrip Strength, and Physical Activity (Sarco-Detect Study).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe main objective of the Sarco-Detect study was to evaluate diagnostic tools-bioelectrical impedance analysis (BIA) and handgrip strength (HGS)-for determining sarcopenia compared with computed tomography (CT). The secondary aim was to evaluate the SARC-F questionnaire as a screening tool and to investigate the impact of muscle loss on quality of life, fatigue, HGS, and the association between previous physical activity and muscle loss.
methodsThe study was conducted at the University Cancer Center Schleswig-Holstein. To assess muscle mass status, BIA and HGS were measured in patients with cancer and compared with CT. Additionally, EORTC QLQ-C30, FACIT-Fatigue Scale, BSA, and SARC-F questionnaires were administered.
resultsOne hundred thirty one patients were recruited. Fourteen patients showed a CT-SMI below the reference values by Van der Werf et al. (2018). Thirteen patients showed reduced HGS. CT-SMI and HGS correlated significantly (r = 0.492, p = 0.001). The phase angle of the BIA correlated significantly with CT-SMI (r = 0.441, p = 0.001) and HGS (r = 0.493, p = 0.001). Patients with reduced HGS presented significantly higher appetite loss compared with patients with preserved HGS. Patients with preserved HGS showed a higher quality of life than patients with reduced HGS. FACIT-Fatigue scores differed significantly between patients with reduced HGS and those with preserved HGS (F(1, 104) = 3.991, p = 0.048; U = 321.000, Z = -2.088, p = 0.037). Activity index correlated moderately with fatigue symptoms and quality of life. The SARC-F showed a sensitivity of 18.8% and specificity of 96.6% for HGS, and a sensitivity of 31.3% and specificity of 90.7% for CT-SMI.
conclusionsCT-SMI and HGS correlated positively and significantly. The BIA phase angle correlated with CT-SMI and HGS. Reduced HGS is associated with increased appetite loss, higher fatigue, and lower quality of life. SARC-F questionnaire appears suitable for identifying patients without sarcopenia.
trial registrationGerman Clinical Trials Register: DRKS00035258.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.